Low systemic ganciclovir exposure and preemptive treatment failure of cytomegalovirus reactivation in a transplanted child

Canadian Journal of Clinical Pharmacology

Volumn 18, Issue 2, 2011, Pages

  Autmizguine, Julie ^a   Théôret, Yves ^a   Launay, Elise ^a   Duval, Michel ^a   Rousseau, Céline ^a   Tapiéro, Bruce ^a   Boivin, Guy ^b   Ovetchkine, Philippe ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Cytomegalovirus; Ganciclovir; Pediatric; Pharmacokinetic; Resistance

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FOSCARNET; GANCICLOVIR; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY; VIRUS DNA; MEPREDNISONE; ANTIVIRUS AGENT;

ANTIVIRAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA SEQUENCE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG TREATMENT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; PRESCHOOL CHILD; TRANSPLANTATION; VIRAL CLEARANCE; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION; VIRUS STRAIN; ANAMNESIS; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CHILDHOOD DISEASE; CLINICAL FEATURE; DRUG EXPOSURE; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECOMMENDED DRUG DOSE; THROMBOCYTOPENIA; UMBILICAL CORD BLOOD TRANSPLANTATION; VIRUS IDENTIFICATION; ANTIVIRAL RESISTANCE; METHODOLOGY; TREATMENT FAILURE; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; DRUG MONITORING; DRUG RESISTANCE, VIRAL; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; TREATMENT FAILURE; VIRUS ACTIVATION;

EID: 79959839584     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153(3):478-88.
2. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009;113(23):5711-9.
3. Albano MS, Taylor P, Pass RF, et al. Umbilical cord blood transplantation and cytomegalovirus: Posttransplantation infection and donor screening. Blood 2006;108(13):4275-82.
4. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118(3):173-8.
5. Small LN, Lau J, Snydman DR. Preventing postorgan transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006;43(7):869-80.
6. Meijer E, Boland GJ, Verdonck LF. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev 2003;16(4):647-57.
7. Eckle T, Prix L, Jahn G, et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000;96(9):3286-9.
8. Boivin G, Chou S, Quirk MR, Erice A, Jordan MC. Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J Infect Dis 1996;173(3):523-8.
9. Zhang D, Lapeyraque AL, Popon M, Loirat C, Jacqz-Aigrain E. Pharmacokinetics of ganciclovir in paediatric renal transplant recipients. Pediatr Nephrol 2003;18(9):943-8.
10. Erice A, Borrell N, Li W, Miller WJ, Balfour HH, Jr. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J Infect Dis 1998;178(2):531-4.
11. Boivin G, Gilbert C, Morissette M, Handfield J, Goyette N, Bergeron MG. A case of ganciclovirresistant cytomegalovirus (CMV) retinitis in a patient with AIDS: longitudinal molecular analysis of the CMV viral load and viral mutations in blood compartments. AIDS 1997;11(7):867-73.
12. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002;99(4):1159-64.
13. Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005;49(3):873-83.
14. Faulds D, Heels R. Ganciclovir: a review of its antiviral activities, pharmacokinetic properties and therapeutic efficacy cytomegalovirus infections. Drugs 1990;39:597-638.
15. Fletcher C, Sawchuk R, Chinnock B, Miranda P, Balfour HH. Human pharmacokinetics for the antiviral drug DHPG. Clin Parmacol Ther 1986;40: 281-6.
16. Piketty C, Bardin C, Gilquin J, Gairard A, Kazatchkine MD, Chast F. Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis. Clin Microbiol Infect 2000;6(3):117-20.
17. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005;79(11):1477-83.
18. Vethamuthu J, Feber J, Chretien A, Lampe D, Filler G. Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. Pediatr Transplant 2007;11(3):301-5.